- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Allogene Therapeutics is a biotechnology business based in the US. Allogene Therapeutics shares (ALLO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.09 – an increase of 9.71% over the previous week. Allogene Therapeutics employs 232 staff and has a trailing 12-month revenue of around $43,000.
Our top picks for where to buy Allogene Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Allogene Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ALLO. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Allogene Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Allogene Therapeutics stock price (NASDAQ: ALLO)
Use our graph to track the performance of ALLO stocks over time.Allogene Therapeutics shares at a glance
Information last updated 2024-12-18.
| Latest market close | $2.09 |
|---|---|
| 52-week range | $1.78 - $5.78 |
| 50-day moving average | $2.53 |
| 200-day moving average | $2.91 |
| Wall St. target price | $9.04 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.55 |
Is it a good time to buy Allogene Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Allogene Therapeutics price performance over time
Historical closes compared with the close of $1.95 from 2024-12-23
| 1 week (2024-12-18) | 2.36% |
|---|---|
| 1 month (2024-11-25) | -14.47% |
| 3 months (2024-09-25) | -25.57% |
| 6 months (2024-06-25) | -18.75% |
| 1 year (2023-12-22) | -36.27% |
|---|---|
| 2 years (2022-12-23) | -67.28% |
| 3 years (2021-12-23) | 15.66 |
| 5 years (2019-12-24) | 26.99 |
Allogene Therapeutics financials
| Revenue TTM | $43,000 |
|---|---|
| Gross profit TTM | $243,000 |
| Return on assets TTM | -25.82% |
| Return on equity TTM | -54.15% |
| Profit margin | 0% |
| Book value | $2.21 |
| Market Capitalization | $399.4 million |
TTM: trailing 12 months
Allogene Therapeutics share dividends
We're not expecting Allogene Therapeutics to pay a dividend over the next 12 months.
Allogene Therapeutics share price volatility
Over the last 12 months, Allogene Therapeutics's shares have ranged in value from as little as $1.7801 up to $5.775. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Allogene Therapeutics's is 0.836. This would suggest that Allogene Therapeutics's shares are less volatile than average (for this exchange).
Allogene Therapeutics overview
Allogene Therapeutics, Inc. , a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18. 2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.
Frequently asked questions
nullWhat percentage of Allogene Therapeutics is owned by insiders or institutions?
Currently 17.423% of Allogene Therapeutics shares are held by insiders and 80.2% by institutions. How many people work for Allogene Therapeutics?
Latest data suggests 232 work at Allogene Therapeutics. When does the fiscal year end for Allogene Therapeutics?
Allogene Therapeutics's fiscal year ends in December. Where is Allogene Therapeutics based?
Allogene Therapeutics's address is: 210 East Grand Avenue, South San Francisco, CA, United States, 94080 What is Allogene Therapeutics's ISIN number?
Allogene Therapeutics's international securities identification number is: US0197701065 What is Allogene Therapeutics's CUSIP number?
Allogene Therapeutics's Committee on Uniform Securities Identification Procedures number is: 019770106
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question